{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04245436",
            "orgStudyIdInfo": {
                "id": "Strawn AtLAS-A"
            },
            "organization": {
                "fullName": "University of Cincinnati",
                "class": "OTHER"
            },
            "briefTitle": "Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)",
            "officialTitle": "Acute, Double-blind, Adaptively Randomized Treatment With Duloxetine or Escitalopram, Followed by Open-label Naturalistic Follow-up.",
            "acronym": "AtLAS-A",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "acute-and-long-term-antidepressant-treatment-success-in-adolescents-with-anxiety-atlas-a"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-01-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-01-07",
            "studyFirstSubmitQcDate": "2020-01-27",
            "studyFirstPostDateStruct": {
                "date": "2020-01-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-13",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jeffrey Strawn, MD",
                "investigatorTitle": "Associate professor",
                "investigatorAffiliation": "University of Cincinnati"
            },
            "leadSponsor": {
                "name": "University of Cincinnati",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.",
            "detailedDescription": "To identify predictors of the magnitude and trajectory of response to flexibly-dosed duloxetine and escitalopram response in adolescents with anxiety, including those with depressive symptoms. And also to examine long-term predictors of sustained response and relapse in adolescents. To examine predictors of developing depressive disorders in anxious adolescents."
        },
        "conditionsModule": {
            "conditions": [
                "Anxiety",
                "Depressive Symptoms"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Double Blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Duloxetine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients randomized to duloxetine, treatment will be initiated at 30 mg qAM through Week 4 (V5) (consistent with the registration trial for duloxetine in pediatric patients with generalized anxiety disorder). Then, duloxetine will be increased to 60 mg qAM at Week 4 (V5) and will be continued at this dose until Week 6 (V6) or the end of the acute phase of the study. Beginning at Week 6 (V6), duloxetine may be increased to 90 mg daily and at Week 8 (V7), may be increased to 120 mg daily.",
                    "interventionNames": [
                        "Drug: Duloxetine"
                    ]
                },
                {
                    "label": "Escitalopram",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.",
                    "interventionNames": [
                        "Drug: Escitalopram"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Duloxetine",
                    "description": "Encapsulated duloxetine 30 mg, 60 mg; once-daily",
                    "armGroupLabels": [
                        "Duloxetine"
                    ],
                    "otherNames": [
                        "Cymbalta",
                        "Irenka"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Escitalopram",
                    "description": "Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily",
                    "armGroupLabels": [
                        "Escitalopram"
                    ],
                    "otherNames": [
                        "Lexapro"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from Baseline in Pediatric Anxiety Rating Scale (PARS) severity score",
                    "description": "The PARS is a clinician-rated instrument for assessing the severity of anxiety symptoms associated with common anxiety disorders in children and adolescents. The PARS score is derived by summing 5 of the 7 severity/impairment/interference items (2, 3, 5, 6, and 7)",
                    "timeFrame": "Baseline to Week 24 months (Early Term)"
                },
                {
                    "measure": "Change from Baseline in the Clinical Global Impression of Severity (CGI-S)",
                    "description": "CGI-S is a seven point scale where 1=Normal and 7=Among the most extremely ill patients.",
                    "timeFrame": "Baseline to Week 10 (Early Term)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Written, informed assent and consent.\n* Patients, parent/guardian/LAR must be fluent in the English.\n* 12 to 17 years of age, inclusive, at Screening.\n* Patients must meet DSM-512 criteria for generalized, social and/or separation anxiety disorder and/or panic disorder, confirmed by the MINI-KID.\n* Caregiver who is willing to consent to be responsible for safety monitoring of the patient, provide information about the patient's condition, oversee the administration of the investigational product.\n* No clinically significant abnormalities on physical examination.\n* Negative pregnancy test at Screening in females.\n* Negative urine drug screen at Screening.\n* Sexually active patients must practice a reliable method of contraception (Section 15.0) that will continue for the duration of the study and for a minimum of 30 days following the end of study participation. Reliable methods of contraception are defined below; other forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted:\n\n  1. Surgical sterilization\n  2. Oral contraceptives (e.g. estrogren-progestin combination or progestin)\n  3. Transdermally-delivered contraceptives (e.g., Ortho-Evra), depot injections (e.g., Depo-Provera)\n  4. Vaginal contraceptive ring (e.g., NuvaRing), contraceptive implants (e.g., Implanon, Norplant II/Jadelle)\n  5. An intrauterine device\n  6. Diaphragm plus condom.\n\nExclusion Criteria:\n\n* DSM-512 diagnosis other than generalized anxiety, social anxiety, separation anxiety or panic disorder(s) that is the primary focus of treatment.\n* A history of intellectual disability.\n* Suicide risk as determined by either: (1) any suicide attempt within the past 6 months and/or (2) significant risk at Visit 1 (Screening) or Visit 2 (Baseline), as judged by the Investigator.\n* Allergy, intolerance, non-response or hypersensitivity to escitalopram or duloxetine.\n* Subjects taking other medications that require a taper or washout of more than 5 days.\n* Patients who have initiated/terminated psychotherapy/behavior therapy within 1 month before Visit 2 (Baseline), or who plan to initiate/change said therapies during the course of the study will be excluded; if the patient is engaged in psychotherapy, it must have been stable for 1 month prior to baseline.\n* A clinically-significant medical illness.\n* QTc \\>450 in males / \\>460 in females (prolonged QTc based on American Heart Association recommendations for Standardization and Interpretation of the EKG81\n* Alcohol or substance use disorder within the past 6 months (nicotine use is permitted).\n* Positive urine pregnancy test/pregnancy or breast feeding.\n* A positive urine drug screen.\n* Patients who are unable to swallow capsules.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jeffrey R Strawn, MD",
                    "role": "CONTACT",
                    "phone": "513-558-4315",
                    "email": "strawnjr@uc.edu"
                },
                {
                    "name": "Heidi K Schroeder, BS",
                    "role": "CONTACT",
                    "phone": "513-558-4422",
                    "email": "heysehk@uc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jeffrey R Strawn, MD",
                    "affiliation": "University of Cincinnati",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Cincinnati",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jeffrey R Strawn, MD",
                            "role": "CONTACT",
                            "phone": "513-558-7700",
                            "email": "strawnjr@uc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003863",
                    "term": "Depression"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4324",
                    "name": "Anxiety Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depressive Symptoms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068736",
                    "term": "Duloxetine Hydrochloride"
                },
                {
                    "id": "D000089983",
                    "term": "Escitalopram"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000000928",
                    "term": "Antidepressive Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000068760",
                    "term": "Serotonin and Noradrenaline Reuptake Inhibitors"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7104",
                    "name": "Dexetimide",
                    "relevance": "LOW"
                },
                {
                    "id": "M17983",
                    "name": "Citalopram",
                    "relevance": "LOW"
                },
                {
                    "id": "M2732",
                    "name": "Escitalopram",
                    "asFound": "Length",
                    "relevance": "HIGH"
                },
                {
                    "id": "M299",
                    "name": "Duloxetine Hydrochloride",
                    "asFound": "Self-management",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M12575",
                    "name": "Norepinephrine",
                    "relevance": "LOW"
                },
                {
                    "id": "M305",
                    "name": "Serotonin and Noradrenaline Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}